Close menu




BAYER AG NA O.N.

Photo credits: pixabay.com

Commented by Armin Schulz on July 17th, 2025 | 07:05 CEST

Bayer, NetraMark, Evotec: How AI Research is accelerating returns and could optimize your portfolio

  • AI
  • Biotechnology
  • Biotech
  • Pharma

In 2025, the healthcare industry is undergoing a radical transformation driven by AI and advanced technologies. While pharmaceutical giants struggle with cost pressures and regulatory hurdles, algorithms are revolutionizing drug development by decoding clinical data in record time and enabling personalized therapies. In this period of disruption, innovative strength will determine victory or decline. Three companies are at the forefront of this shift: Bayer, with its broad portfolio; NetraMark, leveraging AI-powered data analysis; and Evotec, with its disruptive research collaborations. Find out what is currently driving these stocks.

Read

Commented by Fabian Lorenz on July 16th, 2025 | 07:25 CEST

WINNING STOCKS for the second half of the year!? Rheinmetall, Bayer, and Hotstock PanGenomic Health

  • Healthcare
  • healthtech
  • Defense
  • Pharma

Hard to believe: Bayer shares are among the winners in 2025. And even the news flow is positive. Does the Leverkusen-based company even have a new blockbuster in the pipeline? What do analysts say? PanGenomic Health shares could be among the stars of the second half of the year. With a new health app, the Company is entering a billion-dollar market in the US and benefiting from the Trump administration. If it succeeds in securing market share, the stock should have plenty of upside potential. Analysts believe that the air is getting thinner for Rheinmetall shares. However, it is likely only a matter of time before the EUR 2,000 mark is broken.

Read

Commented by Armin Schulz on July 9th, 2025 | 07:05 CEST

Liver cancer breakthrough fuels billion-dollar market: How Bayer, Vidac Pharma, and Novo Nordisk can now power your portfolio

  • Biotechnology
  • Biotech
  • Pharma
  • Innovations

The pharmaceutical industry is undergoing its biggest upheaval in decades. Megatrends such as cancer treatment, fueled by recent breakthroughs like the EMA approval of the liver cancer therapy Lenvima®/Keytruda®, and revolutionary therapies for diabetes and obesity are generating billion-dollar markets. Those who understand these growth drivers will identify lucrative opportunities. Innovative active ingredients are not only changing medicine but also unlocking exceptional return potential for forward-thinking investors. This dynamic draws attention directly to the strategies of Bayer, Vidac Pharma, and Novo Nordisk.

Read

Commented by Fabian Lorenz on July 8th, 2025 | 07:05 CEST

Rheinmetall above EUR 2,000? Bayer shares exhausted? NetraMark Holdings with lots of upside potential!

  • Biotechnology
  • Pharma
  • Defense

It seems only a matter of time before Rheinmetall shares break through the EUR 2,000 barrier. Increasingly, analysts are setting price targets above this mark. And operations are running smoothly, as demonstrated by the latest ammunition order and the Company's participation in the German government's billion-euro investment program. NetraMark, on the other hand, does not have to invest billions in research and development. The AI specialist is still an insider tip. However, the first study is now available, and analysts anticipate over 50% upside potential. In contrast, analysts see the end of the price fireworks at Bayer. Are they right?

Read

Commented by André Will-Laudien on July 4th, 2025 | 07:05 CEST

Lightning on the horizon in the biotech sector: Refinancing on the rise! Keep an eye on Formycon, PanGenomic Health, Bayer, and Novo Nordisk

  • Biotechnology
  • Biotech
  • healthtech
  • Pharma

In the first half of 2025, the biotech sector demonstrated resilience and innovation despite macroeconomic uncertainties. Venture capital financing reached an impressive USD 6.5 billion, with a focus on companies with clinically validated data. Large financing deals such as the USD 365 million for Pathos AI underscore the strategic investor focus on AI and digitalization. The IPO market remains highly selective, but strong stock market debuts such as that of Caris Life Sciences are sending positive signals. At the same time, the M&A sector is booming with billion-dollar acquisitions by pharmaceutical giants such as J&J and Novo. So far in 2025, the biotech sector has demonstrated targeted capital allocation, dynamic consolidation, and growing confidence in medical breakthroughs. Here are a few ideas for a balanced portfolio of opportunities.

Read

Commented by André Will-Laudien on June 30th, 2025 | 07:35 CEST

Takeover fever! Biotech and artificial intelligence boost Evotec, NetraMark Holdings, Novo Nordisk, and Bayer

  • Biotechnology
  • Biotech
  • Pharma
  • AI

The biotech sector is currently undergoing an exciting transformation, as big data and artificial intelligence are rapidly changing the way new drugs are discovered, developed, and tested. The use of learning algorithms allows molecular target structures to be identified more quickly and potential active ingredients to be evaluated more efficiently. Start-ups and established players alike are increasingly turning to data-driven platforms to reduce research costs and increase the success rate of clinical trials. As a result, capital is increasingly flowing into companies that use modern data analysis to drive biotechnology. Approaches that enable personalized medicine - treatments precisely tailored to an individual's specific condition - are in particularly high demand. For investors, this represents a promising growth sector with enormous disruptive potential. But who are the most interesting players?

Read

Commented by André Will-Laudien on June 26th, 2025 | 07:00 CEST

New biotech boom ignites: Are Evotec, BioNxt, Bayer, Novo Nordisk, and Formycon poised for the next price surge?

  • Biotechnology
  • Biotech
  • Pharma

The biotechnology industry is currently experiencing a remarkable renaissance. Innovations in personalized medicine, advances in mRNA technologies, and new therapeutic approaches to cancer and autoimmune diseases are fueling investor interest worldwide. In this dynamic environment, established players such as Evotec and Bayer, as well as specialized up-and-comers like BioNxt and Formycon, are moving into the spotlight of strategic investments. While Evotec scores with its strong partner network, Bayer is working on a realignment with a focus on promising research. BioNxt impresses with a lean business model and promising pipeline products in the field of drug delivery. Formycon, on the other hand, is benefiting from the biosimilar boom and is currently undergoing a turnaround. The industry is highly innovation-driven, and those who bet on the right players could reap above-average rewards.

Read

Commented by Fabian Lorenz on June 20th, 2025 | 06:55 CEST

Declaration of war on the pharmaceutical industry? Bayer, Novo Nordisk, and insider tip PanGenomic Health

  • healthtech
  • Biotechnology
  • Pharma

Has US Health Secretary Robert F. Kennedy Jr. declared war on the traditional pharmaceutical industry? That is certainly what former Trump press secretary and current podcaster Anthony Scaramucci seems to think. The reason for this is the complete overhaul of the US Vaccine Advisory Committee. One company set to benefit from the new US Health Secretary is PanGenomic Health. The Company plans to launch a new digital health and alternative medicine business this year. If it manages to secure even a small share of this billion-dollar market, its share price could multiply. The price target for Novo Nordisk was recently reduced. The stock is working on bottoming out, and there was a success for the blockbuster in the US. Bayer's stock is trending favorably. Regular positive news is currently overshadowing the legal disputes in the US. There was recently some positive news to report there.

Read

Commented by Armin Schulz on June 17th, 2025 | 07:25 CEST

Pharmaceutical revolution 2025: Why Novo Nordisk, NetraMark Holdings, and Bayer are doubling their returns through AI efficiency

  • Biotechnology
  • AI
  • Pharma

The pharmaceutical industry is undergoing a digital transformation in 2025. Artificial intelligence is decoding active ingredients in record time, big data is driving personalized therapies, and blockchain is securing supply chains. These technologies are catapulting efficiency skyward and dramatically reducing development costs in a billion-dollar market that is growing steadily due to demographic change. Those who identify the right companies now will benefit from the disruptive wave. Therefore, we look at three companies that could benefit from this change: Novo Nordisk, NetraMark Holdings, and Bayer.

Read

Commented by André Will-Laudien on June 13th, 2025 | 07:00 CEST

The three IT musketeers – AI, high tech, quantum computing! NetraMark Holdings, Bayer, Novo Nordisk, and D-Wave

  • AI
  • hightech
  • computing
  • Pharma
  • Biotechnology

A new edition of GTC 2025 is currently underway in the French capital, Paris, where NVIDIA CEO Jensen Huang spoke at length about the future of artificial intelligence. As usual, he also made some interesting comments about quantum computers. In the eyes of the NVIDIA CEO, quantum computer technology has reached a decisive turning point and will soon be able to solve some interesting problems that would take even NVIDIA's most advanced AI systems years of computing time to solve. The requirements go beyond pattern recognition, automation, and real-time decisions. Recently, AI has also been playing a significant role in medicine and pharmaceutical development. For some stocks, there is, therefore, a daily reason to reach new highs. Now is the time for investors to focus!

Read